LAPDIGE Trademark

Trademark Overview


On Thursday, June 17, 2021, a trademark application was filed for LAPDIGE with the United States Patent and Trademark Office. The USPTO has given the LAPDIGE trademark a serial number of 90779988. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Monday, July 8, 2024. This trademark is owned by Bristol-Myers Squibb Company. The LAPDIGE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical pre...
lapdige

General Information


Serial Number90779988
Word MarkLAPDIGE
Filing DateThursday, June 17, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateMonday, July 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 22, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 3, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Friday, September 3, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, June 21, 2021NEW APPLICATION ENTERED
Wednesday, March 9, 2022ASSIGNED TO EXAMINER
Wednesday, March 16, 2022NON-FINAL ACTION WRITTEN
Wednesday, March 16, 2022NON-FINAL ACTION E-MAILED
Wednesday, March 16, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 13, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 13, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, September 14, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 13, 2022EXAMINERS AMENDMENT -WRITTEN
Thursday, October 13, 2022EXAMINERS AMENDMENT E-MAILED
Thursday, October 13, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, October 13, 2022EXAMINER'S AMENDMENT ENTERED
Thursday, October 13, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 2, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 22, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 22, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 17, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, July 10, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 10, 2023SOU EXTENSION 1 FILED
Monday, July 10, 2023SOU EXTENSION 1 GRANTED
Wednesday, July 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, January 4, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 8, 2024SOU TEAS EXTENSION RECEIVED
Monday, July 8, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 8, 2024SOU EXTENSION 3 FILED
Monday, July 8, 2024SOU EXTENSION 3 GRANTED
Tuesday, January 2, 2024SOU EXTENSION 2 GRANTED
Tuesday, January 2, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 2, 2024SOU EXTENSION 2 FILED